This clinical trial is focused on studying a rare type of cancer called adrenocortical carcinoma, which affects the outer layer of the adrenal glands. The study aims to evaluate the effectiveness of adding a hormone called progesterone to a standard chemotherapy treatment. The chemotherapy regimen includes medications such as cisplatin, etoposide, and doxorubicin, which are administered through an intravenous infusion, meaning they are given directly into a vein. Additionally, a medication called mitotane is included, which is taken orally in tablet form. Some participants will receive a placebo instead of progesterone to compare the outcomes.
The purpose of this study is to assess how well the combination of these treatments works in patients with advanced or metastatic adrenocortical carcinoma, meaning the cancer has spread to other parts of the body. Participants will be randomly assigned to receive either the combination of chemotherapy with progesterone or chemotherapy with a placebo. The study will monitor the participants over a period to see how the cancer responds to the treatment.
Throughout the study, participants will receive regular medical check-ups and monitoring to ensure their safety and to track the progress of the treatment. The study is designed to provide valuable information on whether adding progesterone to the standard chemotherapy regimen can improve outcomes for patients with this challenging form of cancer.
Italy 
